Literature DB >> 6223812

In vitro activity of teichomycin A 2 in comparison with penicillin and vancomycin against gram-positive cocci.

A Bauernfeind, C Petermüller.   

Abstract

Teichomycin A2, a glycopeptide antibiotic from Actinoplanes teichomyceticus, was tested for its in vitro activity against 190 gram-positive cocci under variable test conditions. Minimum inhibitory concentrations were fairly insensitive to both changes of inoculum size and pH, but were higher on agar than in broth. Teichomycin was about as active as vancomycin against Staphylococcus aureus (both methicillin resistant and sensitive strains), slightly inferior to vancomycin against Staphylococcus epidermidis, and distinctly more active against Streptococcus faecalis.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6223812     DOI: 10.1007/bf02019971

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  13 in total

1.  A simple test system for the separation of staphylococci from micrococci.

Authors:  K H Schleifer; W E Kloos
Journal:  J Clin Microbiol       Date:  1975-03       Impact factor: 5.948

Review 2.  Antibiotic resistance plasmids of Staphylococcus aureus and their clinical importance.

Authors:  R W Lacey
Journal:  Bacteriol Rev       Date:  1975-03

3.  Comparison of the in vitro activities of teichomycin A2 and vancomycin against staphylococci and enterococci.

Authors:  M H Cynamon; P A Granato
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

4.  Lysostaphin disk test for routine presumptive identification of staphylococci.

Authors:  B Poutrel; J P Caffin
Journal:  J Clin Microbiol       Date:  1981-06       Impact factor: 5.948

5.  [Pathogenic spectrum for septicemia, 1974-1980].

Authors:  P M Shah; E B Helm; W Stille
Journal:  Dtsch Med Wochenschr       Date:  1981-04-03       Impact factor: 0.628

6.  Piperacillin, a new penicillin active against many bacteria resistant to other penicillins.

Authors:  K P Fu; H C Neu
Journal:  Antimicrob Agents Chemother       Date:  1978-03       Impact factor: 5.191

7.  Teichomycins, new antibiotics from Actinoplanes teichomyceticus Nov. Sp. I. Description of the producer strain, fermentation studies and biological properties.

Authors:  F Parenti; G Beretta; M Berti; V Arioli
Journal:  J Antibiot (Tokyo)       Date:  1978-04       Impact factor: 2.649

8.  [Resistance of methicillin-resistant staphylococci to new cephalosporin antibiotics (author's transl)].

Authors:  F H Kayser
Journal:  Infection       Date:  1980       Impact factor: 3.553

9.  Variable tolerance of a clinical isolate of Staphylococcus epidermidis from an infected hydrocephalus shunt for several beta-lactam antibiotics, vancomycin and fosfomycin.

Authors:  W H Traub
Journal:  Chemotherapy       Date:  1981       Impact factor: 2.544

10.  A new type of penicillin resistance of Staphylococcus aureus.

Authors:  L D Sabath; N Wheeler; M Laverdiere; D Blazevic; B J Wilkinson
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

View more
  14 in total

1.  Evaluation of teicoplanin and vancomycin disk susceptibility tests.

Authors:  A L Barry; C Thornsberry; R N Jones
Journal:  J Clin Microbiol       Date:  1986-01       Impact factor: 5.948

2.  Binding of teicoplanin to human serum albumin.

Authors:  A Assandri; A Bernareggi
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

3.  Susceptibility of gram-positive aerobic cocci to the new cephalosporin HR 810.

Authors:  A Bauernfeind
Journal:  Eur J Clin Microbiol       Date:  1983-08       Impact factor: 3.267

4.  The activity of vancomycin and teicoplanin alone and in combination with gentamicin or ampicillin against Streptococcus faecalis.

Authors:  H Y Chen; J D Williams
Journal:  Eur J Clin Microbiol       Date:  1984-10       Impact factor: 3.267

5.  In vitro activity of teicoplanin and vancomycin against anaerobes.

Authors:  Y Glupczynski; M Labbe; F Crokaert; E Yourassowsky
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

6.  In vitro activity and human pharmacokinetics of teicoplanin.

Authors:  L Verbist; B Tjandramaga; B Hendrickx; A Van Hecken; P Van Melle; R Verbesselt; J Verhaegen; P J De Schepper
Journal:  Antimicrob Agents Chemother       Date:  1984-12       Impact factor: 5.191

7.  Activities of daptomycin and teicoplanin against Staphylococcus haemolyticus and Staphylococcus epidermidis, including evaluation of susceptibility testing recommendations.

Authors:  D E Low; A McGeer; R Poon
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

8.  Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria.

Authors:  A L Barry; R N Jones; T L Gavan; C Thornsberry
Journal:  J Clin Microbiol       Date:  1987-09       Impact factor: 5.948

9.  Prospective randomized clinical trial of teicoplanin for empiric combined antibiotic therapy in febrile, granulocytopenic acute leukemia patients.

Authors:  A Del Favero; F Menichetti; R Guerciolini; G Bucaneve; F Baldelli; F Aversa; A Terenzi; S Davis; S Pauluzzi
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

10.  Clinical efficacy and safety of teicoplanin in the treatment of gram-positive infections.

Authors:  P Kempf; H Pompetzki; A Oppermann; R Wittenberger; J Siebert; J J Fell; H A Dieterich
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.